-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QjjhSFUau86cceUkq9qcjbjx3gupUX7I3PmulBttoovfvA0aj1FQ93rMBBIq5q7y BPqZzRh7laQ1rfv1bWVg0A== 0001209191-04-028435.txt : 20040527 0001209191-04-028435.hdr.sgml : 20040527 20040527183917 ACCESSION NUMBER: 0001209191-04-028435 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040527 FILED AS OF DATE: 20040527 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 BUSINESS ADDRESS: STREET 1: 790 MEMORIAL DR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172520700 MAIL ADDRESS: STREET 1: 790 MEMORIAL DR CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHARP PHILIP A CENTRAL INDEX KEY: 0001226295 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50743 FILM NUMBER: 04836238 BUSINESS ADDRESS: STREET 1: BIOGEN INC LEGAL DEPARTMENT STREET 2: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6176792000 MAIL ADDRESS: STREET 1: BIOGEN INC LEGAL DEPARTMENT STREET 2: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 bob50698ps.xml MAIN DOCUMENT DESCRIPTION X0202 3 2004-05-27 0 0001178670 ALNYLAM PHARMACEUTICALS INC ALNY 0001226295 SHARP PHILIP A C/O ALNYLAM PHARMACEUTICALS, INC. 300 THIRD STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 233333 D Stock Option (right to buy) 0.95 2013-11-06 Common Stock 36842 D Series B Convertible Preferred Stock Common Stock 31578 D Reflects a 1-for-1.9 reverse stock split, which became effective on May 7, 2004, pursuant to which the number of shares of common stock was divided by 1.9. The stock option vests as to 25% of the shares on November 6, 2004 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter. Automatically converts into common stock upon the closing of the issuer's initial public offering of common stock. N/A Reflects a 1-for-1.9 reverse stock split, which became effective on May 7, 2004, pursuant to which (i) the number of shares of common stock underlying the option was divided by 1.9 and (ii) the exercise price of the option was multiplied by 1.9. Reflects a 1-for-1.9 reverse stock split, which became effective on May 7, 2004, pursuant to which each share of Series B Preferred Stock will automatically convert into approximately 0.53 shares of common stock upon the closing of the issuer's initial public offering of common stock. /s/ Phillip A. Sharp 2004-05-27 EX-24 2 ps-poa.txt POWER OF ATTORNEY LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of John M. Maraganore and Barry E. Greene, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Alnylam Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act"); (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of May, 2004. Phillip A. Sharp ---------------------------------------- Print Name /s/ Phillip A. Sharp ---------------------------------------- Signature if individual By: ------------------------------------- Signature if entity Title: ---------------------------------- Print title of person signing if entity -----END PRIVACY-ENHANCED MESSAGE-----